Ingenol-3-Angelate Suppresses Growth of Melanoma Cells and Skin Tumor Development by Downregulation of NF-κB-Cox2 Signaling

ABCDF 1 Dunwei Wang
ABCD 2 Pengcheng Liu

Corresponding Author: Pengcheng Liu, e-mail: petitegsetia@yahoo.com
Source of support: Departmental sources

Background: A recent focus in skin cancer prevention intervenes through modulating molecular links between inflammation and cell growth signaling, such as NF-κB. This study elucidates the effect of a non-tumor promoting phorbol ester, ingenol-3-angelate (I3A), on the growth of human melanoma cells and on the 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced skin inflammation and 7,12-Dimethylbenz(a)anthracene (DMBA)-induced skin carcinoma in mice.

Material/Methods: Cell viability was assessed by MTT assay, cell proliferation by clonogenic assay, apoptosis and cell cycle arrest was analyzed by flow cytometry, protein expression was studied by IHC and Western blotting, and gene expression by qPCR.

Results: I3A suppressed the survival and proliferation of human melanoma cells with estimated IC50 values around 38 and 46 μM for A2058 and HT144 cell, respectively. I3A activated the protein levels of PKCδ and PKCe, which induced apoptosis by activating caspase-9 and caspase-3 followed by lowering of mitochondrial membrane potential and enhancing DNA fragmentation. I3A induced G1 phase cell cycle arrest as well as G2/M phase arrest in both cell lines. I3A inhibited the levels of NF-κB p65 protein as well as phosphorylation of p65 and its nuclear translocation. I3A suppressed the gene expression of NF-κB, COX-2 and iNOS. I3A inhibited TPA-induced inflammation and epidermal hyperplasia in female ICR mice by downregulating NF-κB and iNOS. I3A suppressed the growth of skin tumor in DMBA-induced mice in dose-dependent manner.

Conclusions: The mechanism of I3A induces apoptosis in human melanoma cells and suppresses skin inflammation and carcinoma via downregulation of NF-κB-iNOS-COX-2 signaling.

MeSH Keywords: Anti-Inflammatory Agents • Apoptosis • Cyclooxygenase 2 • Herbal Medicine • NF-kappa B • Nitric Oxide Synthase Type II

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/906049
Background

Cancer growth and proliferation is mainly due to disruption of the intracellular signaling network that transduces improper signaling in abnormally functioning cells. Targeting uncontrolled signaling cascade inside cells might be a coherent approach in attaining chemoprevention [1–3]. Skin cancer is the most prevalent cancer worldwide, caused primarily by a variety of carcinogens, including UV exposure and chemicals, inducing cellular inflammation signaling and modulating the rate of apoptosis. A recent focus in cancer prevention intervenes though modulating molecular cross-talks between inflammation and cancer growth signaling networks converging on redox-sensitive transcription factor nuclear factor-κB (NF-κB). NF-κB has been directly associated with inflammatory responses, with further links to promotion of carcinogenesis [2–5]. NF-κB-mediated inflammation-driven carcinogenesis involves transactivation of a major molecular target cyclooxygenase-2 (Cox-2) [6]. Cox-2 is involved in prostaglandin (PG) biosynthesis and inflammation and it has been apparent upregulated in various premalignant and malignant tissues [6]. The abnormally high levels of Cox-2 have been shown to be contributory to tumorigenesis in various animal models of cancer, and downregulation of Cox-2 has been spontaneously preventive [7–9]. Various stimuli and mediators have been shown to be involved in transient induction of NF-κB and transactivation of Cox-2, thus eliciting inflammation and consequent tumorigenesis [3,6–9]. Thus, targeted inhibition of NF-κB and Cox-2 has become a promising and practical tool in cancer prevention. A small-molecule drug, 12-O-tetradecanoylphorbol-13-acetate (TPA), a diester of phorbol, is also known as tetradecanoylphorbol acetate, tetradecanoyl phorbol acetate, and phorbol 12-myristate 13-acetate (PMA). TPA is prototype tumor promoter drug acting by activation of protein kinase C (PKC) signal transduction [10,11]. The topical application of TPA on mouse skin has been shown to induce expression levels of Cox-2 by activating transcription factors, mainly NF-κB and activator protein-1 (AP-1). NF-κB is further regulated by a series of upstream kinases, mitogen-activated protein kinases (MAPKs), such as p38 and Erk [12,13]. Thus, TPA-induced skin carcinoma has become an established model for signaling and pharmacological analyses. DMBA is a major class of environmental carcinogens, a prototypical polycyclic aromatic hydrocarbon that promotes tumors in experimental conditions. DMBA administration induces mammary and skin tumors by upregulating the cellular cytosolic receptor, the Aryl hydrocarbon receptor [14]. DMBA further causes activation of NF-κB, which then positively controls transcriptional activity of cell proliferation [15].

Reports suggest that diminishing NF-κB-COX-2 crosstalk may prevent tumorigenesis. Natural compounds and their derivatives have been successfully used in management of cancer growth in cell lines and in animal models. Various natural products and lead molecules have shown to especially modulate the activity of NF-κB and COX-2 in a variety of cancers [16,17–19]. Ingenol-3-angelate (I3A) is a natural diterpene ester obtained from the sap of the plant Euphorbia peplus, which has long been used for treating various ailments, including skin cancers. I3A is a phorbol ester-like compound, a non-tumor promoting diacylglycerol analogue that binds with high affinity to the C1 domains of PKCs and promotes enzyme activation by recruiting PKCs to cellular membranes. The I3A-derived formulation PEP005 was dynamically evaluated in clinical trials for effective treatment of actinic keratosis and basal cell carcinoma and squamous cell carcinoma for inducing primary necrosis, apoptosis, and senescence [20–24]. The topical application of I3A has been shown to suppress mouse and human tumors growth in C57BL/6 and Foxn1nu mouse models [20]. I3A recruited neutrophil influx in tumor cells and induced acute cytotoxicity, leading to cell death by induction of primary necrosis [20]. I3A showed tumor regression activity by binding to classical and novel PKC isosforms and causes tumor vascular disruption, tumoricidal neutrophils recruitment, and cytotoxic T cells generation [22,23,25,26]. Thus, some of the biological effects of I3A are probably mediated by activation of PKCs in living cells. Also, the molecule has been reported to be immunomodulatory and tumor-suppressing in nature; however, the mechanism by which I3A affects skin tumors needs elucidation, especially the role of inflammation and growth-signaling molecules like NF-κB and COX-2. In this study, we investigated the effect of I3A on TPA-induced skin carcinoma in mice and explored the role of NF-κB-COX-2 crosstalk as the underlying molecular mechanisms. We report that TPA induced IkB kinase (IKK) activity in mouse skin, which was subsequently suppressed by topical application of I3A by downregulation of transcription factor NF-κB and COX-2 transactivation.

Material and Methods

Materials

I3A (#16207) was procured from Cayman Chemicals (MI, USA). TPA (#4174S) was purchased from Cell Signaling Technology (MA, USA). 7,12-Dimethylbenz[a]anthracene (DMBA, ≥98% purity) was procured from Santa Cruz Biotechnology (TX, USA). NF-κB activator prostratin was purchased from Sigma-Aldrich Chemicals Co. (MO, USA). Most of other chemicals and reagents were of high purity analytical or molecular grades and were purchased from Sigma-Aldrich, Invitrogen-Thermo Fisher, and Merck-Millipore, unless otherwise mentioned.

Cell culture and drug treatment

Human melanoma cell lines A2058 and HT144 were grown in RPMI 1640 medium (Gibco, Thermo Fisher, USA) supplemented
with 10% FBS (Invitrogen, USA) and 100 IU/ml streptomycin-penicillin (Thermo Fisher, USA) in a CO₂ chamber at 37°C temperature and 95% humidity. Cells were treated with I3A dissolved in DMSO as vehicle control at less than 1% final concentration.

Animal models of skin carcinoma

All the animal experimental procedures were conducted in accordance with the Institutional Animal Ethical Committee with a grant of Animal Ethical Clearance for the animal models and study by LinYi People’s Hospital, Shandong, China.

TAP-induced skin tumor ICR mice model

Female 6-wee-old ICR (Institute of Cancer Research) mice were housed under controlled conditions of 25±3°C temperature and 55±5% humidity with a 12-h light/dark cycle. Mice were given standard laboratory chow and purified sterile drinking water. Mice were shaved at the dorsal side of the skin using an electrical clipper. After shaving, mice were randomly distributed into 4 groups, each containing 5 mice: control (vehicle control, VH); TPA-VH; TPA-I3A 25nmol; and TPA-I3A 50 nmol. The dorsal shaven areas of mice in 3 groups (except control) were topically applied with 10 nmol of TPA dissolved in vehicle control (100 μl of acetone). After 24 h of TPA application, the shaven areas of mice in different groups were topically treated daily twice with either VH or indicated doses of I3A (dissolved in 100 μL of acetone). After 1 week of total treatment time, mice were sacrificed by CO₂ inhalation and subjected to further analyses.

DMBA-induced skin carcinoma in mice

Inbred male Swiss albino mice were housed under controlled conditions of 25±3°C temperature and 55±5% humidity with 12-h light/dark cycle. Four-week-old mice were dorsally shaved with an electrical hair clipper. Hair-removed rats were randomly distributed in to 4 groups: control (vehicle control); DMBA-HV; DMBA-I3A-25 nmol; and DMBA-I3A-50 nmol. The first group of mice, the control group, were applied with 100 μl acetone (vehicle for DMBA) once a week followed by 100 μl sesame oil twice a week. The second group of mice received topical application of DMBA (100 μg/100 μL of acetone) once a week followed by 100 μl sesame oil twice a week. The third group of mice were treated with DMBA (as in the second group) followed by topical application of I3A 25 nmol in 100 μl sesame oil. The fourth group of mice were treated with DMBA (as in the second group) followed by topical application of I3A 50 nmol in 100 μl sesame oil. Vehicle or I3A treatment was continued for 16 weeks. The backs of mice were observed weekly until a palpable tumor was observed in the DMBA-VH group. Mice in all groups were then killed by CO₂ inhalation, and tumor shape and size was recorded and compared among groups.

Cell viability and clonogenic assay

A2058 and HT144 cells were treated with vehicle control or I3A at indicated concentrations for 48 h in 96-well plates. Cell viability was assessed by using the MTT cell viability assay kit (Thermo Fisher, USA) as per the manufacturer’s instructions. After 48 h of treatment, 20 μl of MTT reagent (2 mg/ml) was added to wells containing cells in the plate. Plates were then incubated at 37°C for 2 h. Then, media from wells containing MTT reagent were completely aspirated and wells were dried. Then, 100 μl of DMSO was added to each well to dissolve the formazan crystals formed, and absorbance was recorded at 570 nm in a microplate reader. The cell viability ratio was calculated and values are presented as percentage of control. For clonogenic assay, A2058 and HT144 cells were treated with vehicle control or with I3A at 1 and 5 μM concentrations for 24 h. Then, media were removed and plates were incubated with methanol for 30 min. Cells were then stained with crystal violet for 60 min followed by washing with phosphate-buffered saline (PBS). Then, cell counting was performed under a light microscope (40×). The experiment was performed in triplicate with a minimum of 3 wells per sample in each experiment.

Flow cytometry for apoptosis and cell cycle analyses

A2058 and HT144 cells at 2×10⁶ densities were treated with vehicle control or with I3A at 1 and 5 μM concentrations for 24 h. Apoptosis patterns in cells were assessed by flow cytometry using an Annexin V-FITC Apoptosis Detection Kit II (BD Bioscience, San Jose, CA) as per the manufacturer’s instructions. After treatment, cells were harvested in FACS tubes with cold PBS washing. Cells were then resuspended in binding buffer composed of 10 mM Heps/NaOH pH 7.4, 140 mM NaCl, and 2.5 mM CaCl₂. Cells were then stained with FITC-conjugated annexin V and analyzed by flow cytometry using FACSCalibur (BD Bioscience, USA). For cell cycle analysis, cells were treated with or without I3A as above for 24 h. Cells were harvested and counted by staining with trypan blue. Total 1×10⁶ cells were centrifuged to pellets and fixed in cold 70% ethanol for 60 min at 4°C. Cells were then resuspended in Krishan’s buffer (1 ml) with propidium iodide added (50 μg/ml) for 60 min at 4°C. Cells were washed with cold PBS (PBS) followed by flow cytometry analysis using FACSCalibur (BD Bioscience, USA). The percentage of cells in different phases of cell cycle (G1/G0, S, and G2/M) was determined by the Modfit LT program (Verity Software House, ME, USA) and compared among samples.

Mitochondrial membrane potential (ΔΨm) measurement

Mitochondrial membrane potential (MMP, ΔΨM) in A2058 and HT144 cells was estimated by using JC-10 Mitochondrial Membrane Potential Assay Kit for microplate (Abcam, USA), as per manufacturer’s instructions. Cells were treated with or
without I3A for 24 h in 96-well plates. Then JC-10 dye-loading solution was added at 50 μL/wells and incubated at in CO₂ incubator at 37°C for 30 min followed by addition of 50 μL/wells assay buffer B. The fluorescence intensities of J-aggregates and monomeric forms both were measured at excitation/emission wavelengths 490/525 nm and 490/590 nm using a microplate reader.

DNA fragmentation analysis for apoptosis

DNA fragmentation in A2058 and HT144 cells was assessed by electrophoresis of extracted genomic DNA from cells. Cells at 2×10⁶ densities were treated with or without I3A for 24 h. Cells were harvested and homogenized with 50 μl of lysis buffer containing 50 mM Tris-Cl, 1% NP-40 and 20 mM EDTA. Homogenate was centrifuged at 12,000×g for 15 min at 4°C. Supernatant was collected from whole-cell lysate and treated with 5 μg RNase A and 1% SDS for RNA digestion at 37°C for 2 h. Cell lysate supernatant was subsequently treated with 2.5 μg/μl Proteinase K for protein digestion at 37°C for 2 h. Further DNA isolation was performed and DNA was precipitated by using 10 M ammonium acetate and ethanol. Isolated genomic DNA was dissolved in gel loading buffer for 1% agarose gel electrophoresis. DNA bands were visualized by staining with ethidium bromide under a UV-trans-illuminator.

Protein isolation from cells and tissues

Total cellular protein was isolated from cell cultures by harvesting cells by scraping, washing with cold PBS, and pelleting by centrifugation. Cells were then lysed in RIPA cell lysis buffer: 20 mM Tris pH 7.5, 1.0 mM EDTA, 150 mM NaCl, 2.5 mM sodium pyrophosphate, 1% Triton X-100, 1% sodium vanadate, 1 mM PMSF, and protease inhibitor cocktail. Cells were lysed for 40 min in ice with intermittent vortexing. Lysed cells homogenate was centrifuged at 10,000×g for 10 min at 4°C and supernatant was collected. For certain experiments, proteins were also isolated from nuclear fraction. Cells were homogenized with lysis buffer containing 10 mM Tris-Cl pH 7.5 with 2.0 mM each of MgCl₂, and CaCl₂, 500 mM sucrose and 1 mM PMSF and protease and phosphatase inhibitor cocktails. The homogenate was mixed with 0.5% Igepal CA-360 solution and lysed in ice for 30 min. Cell lysate was centrifuged and supernatant collected was designated as “cytoplasmic fraction”. Pellets were further treated with nuclear extraction buffer containing 20 mM HEPES buffer pH 7.9, 2.0 mM MgCl₂, 500 mM NaCl, 0.2 mM EDTA, 25% (v/v) glycerol, 0.1 M DTT, 1 mM PMSF, and protease and phosphatase inhibitor cocktail. The pellet was vortex-mixed with buffer and kept at ice for 30 min. Cell lysate was then centrifuged at 15,000×g for 15 min at 4°C and supernatant containing “nuclear fraction” was collected. Rat epidermis was collected after sacrifice and 50 mg of tissue was homogenized using a Polytron tissue homogenizer in 500 μl of ice-cold tissue lysis buffer containing 50 mM Tris-HCl (pH 7.4), 20 mM EGTA, 150 mM NaCl, 1 mM dithiothreitol (DTT), 0.5% Triton X 100, 1 mM Na₂VO₃, and 1x protease inhibitor cocktail. Tissue lysates were kept in ice for 30 min with intermittent vortex mixing, followed by centrifugation at 15,000×g for 30 min at 4°C. Clear supernatant was collected and treated as total tissue protein for Western blot analyses. Tumors were extracted from rats and snap frozen in liquid nitrogen. Later, whole-cell protein was isolated from frozen tumors by homogenizing in tissue lysis buffer composed of 50 mM Tris-HCl pH 8.0, 100 mM NaCl, 1% NP-40, 1 mM NaF, and 1mM PMSF with 1x protease inhibitor cocktail.

Western blotting

Proteins isolated were quantified using BCA protein assay kit (Pierce Biotech., USA) following standard methodology. Equivalent amounts of protein (20 μg) per sample were separated on 12% SDS-PAGE. Electrophoresed protein bands were transferred onto PVDF membranes (Merck-Millipore) using a Western blot transfer system (Bio-Rad). Membranes were blocked with 5% fat-free dry milk in PBST buffer (phosphate-buffered saline with 0.1% Tween-20) followed by washing with PBST buffer. Membranes were then subjected to binding with protein specific primary antibodies in recommended dilutions, followed by treatment with respective secondary antibodies. Protein bands were visualized by using an Enhanced Chemiluminescence (ECL) detection kit (Sigma).

Measurement of epidermal hyperplasia

The epidermal thickness in TPA-induced ICR mice skin was measured by removal of skin and fixing in 10% formalin. Skin sections embedded in paraffin sections were cut to 4-μm thickness followed by mounting on polylysine-coated glass slides. Mounted skin sections were then de-paraffinized in xylene and serially rehydrated in graded alcohols. Sections were then stained with hematoxylin and eosin for histological examination. Epidermal thickness in skin sections was measured by visualizing under a light microscope (Leica) at 400× magnification. The infiltrating leukocytes counting in dermis was performed by counting the stained cells and data are presented graphically.

Immunohistochemical analysis and TUNEL staining

Mouse skin was fixed in normal buffered formalin followed by serial dehydration in graded alcohol, then embedded in paraffin. Tissues embedded in paraffin blocks were section-cut into 4 μm size, then processed for antibody treatment. Tissue sections were de-paraffinized and subjected to primary antibody treatment for 24 h at 4°C. Sections were then processed and treated with respective secondary antibodies and visualized using DAB chromogen system (Sigma) under a light microscope.
I3A suppresses survival and proliferation of human melanoma cells

The effect of I3A was analyzed on the growth and proliferation of human melanoma cells A2058 and HT144. Cells were treated with various concentrations of I3A for 24 h, and MTT assay was performed. The cell viability data demonstrate that I3A suppressed the growth of both cell lines in a dose-dependent manner (Figure 1A). The IC50 values estimated for I3A in A2058 and HT144 cells were 38 and 46 μM, respectively. The morphologic changes induced by I3A in A2058 and HT144 cells were imaged under a light microscope (Figure 1B). After 12 h of I3A treatment in a dose-dependent manner, the appearance of cell cytoplasm became granular, volume was reduced, and nuclei constituted the majority of the cellular volume as compared to control. At 24 h of I3A treatment, a portion of cells lost the ability to adhere to the plates. In addition, the clonogenic assay was further performed for analyzing the effect of I3A on the survival and proliferation of melanoma cells. Results of colony formation assay demonstrate that I3A suppressed the proliferation of A2058 and HT144 cells in a dose-dependent manner (Figure 1C). The quantitative estimation of clonogenic assay shows that I3A suppressed proliferation of A2058 cells by 68% and 44% at 1 and 5 μM concentrations, respectively (Figure 1D). The quantitative expression of data in HT144 cells was 72% and 48% inhibition of proliferation at 1 and 5 μM of I3A, respectively. Since I3A is a known activator of the PKC family, similarly confirmed by Western blotting and PKCδ and PKCe proteins from of A2058 and HT144 cell lysates (Figure 1E). As expected, I3A increased the levels of both PKCδ and PKCe proteins in both A2058 and HT144 cell in a dose-dependent manner. The levels of PKCe were partly more induced by I3A as compared to PKCδ in both cell lines and a similar observation has been reported in another melanoma cell line [24]. This result shows that I3A suppressed survival and proliferation of melanoma cells by activation of the PKC family.

I3A induced apoptosis and cell cycle arrest

Activation of PKC members is associated with induction of apoptotic cell death, which was examined by flow cytometry analysis for apoptosis and cell cycle, determination of mitochondrial membrane potential, and Western blotting of apoptosis-related proteins. The effect of I3A on cell proliferation was quantitated by staining cells with Annexin V and PI and FACS analysis (Figure 2A). I3A-treated cells showed induction of apoptosis in dose-dependent manner. I3A 1-μm treatment of A2058 cells caused 14.6% and 11.2% early and late apoptosis, respectively, while I3A 5-μm-treated A2058 cells showed drastic increase in early (38.4%) and late (22.8%) apoptosis. HT144 cells showed a slightly different pattern of apoptosis induction. I3A treatment
of HT144 cells showed 24.6% and 27.5% early apoptosis at 1 and 5 μM, respectively. While I3A-treated HT144 cells showed drastic increase in late apoptosis by 6.8% and 22.4% at 1 and 5 μM, respectively. Apoptosis induction in cells is mediated by mitochondria, which actually is reflected from the mitochondrial membrane potential. Thus, ΔΨM is an important parameter of mitochondrial function and an indicator of healthy cells. ΔΨM was estimated by using JC-10 (a lipophilic cationic dye) staining method, which detects ΔΨM changes in cells. JC-10 forms red fluorescent aggregates in healthy cells while the fluorescence is reduced in necrotic and apoptotic cells because of diffusion of JC-10 monomeric form (green fluorescence). Thus, apoptotic or unhealthy cells show low ΔΨM due to JC-10 monomeric form with green fluorescence. The ELISA analysis (Figure 2B) of I3A-treated cells showed dose-dependent reduction in JC-10 fluorescence at excitation/emission wavelengths 490/525 nm and 490/590 nm. As compared to normal (100%) A2058 cells, I3A-treated cells showed 82.7% and 58.4% reduced relative JC-10 fluorescence levels at 1 and 5 μM concentrations, respectively. Similarly, HT144 cells showed 84.7% and 64.6% JC-10 relative fluorescence as compared to control (100%) at 1 and 5 μM concentrations, respectively. The lowering of ΔΨM directly correlates with induction of apoptosis. Apoptosis induction by I3A was further confirmed by internucleosomal DNA fragmentation assay. In the process of apoptosis, activated nucleases cleave large chromatin structures into smaller fragments (50 to 300 kb), then into small DNA pieces of about 200 base pairs in length. Genomic DNA was isolated from I3A-treated cells and DNA fragmentation pattern was visualized by ethidium bromide staining and agarose gel electrophoresis (Figure 2C). Results show that I3A caused a dose-dependent increase in DNA fragmentation in both cell lines, with more clear observation in A2058 cells. These results show that I3A caused apoptosis induction in both cell lines, which was further confirmed at protein levels by Western blotting (Figure 2D). I3A caused activation of pro-caspase-9 in a dose-dependent manner.
manner in both cell lines. It subsequently activated pro-caspase-3 to cleaved-caspase-3, which further caused cleavage of PARP, a nuclear substrate of caspase-3. Additionally, we also examined the impact of I3A on cell cycle progression by flow cytometry. In both cell lines, I3A caused dose-dependent reduction of cells in S and M in accordance with increases in G1 and M phase population. I3A caused aggregation of A2058 cells in G1 phase by 4.2%, 16.5%, and 22.6% at 0, 1, and 5 μM concentrations, respectively. Remarkably, I3A also caused aggregation of cells in M phase by 12.1%, 18.6%, and 26.1% at 0, 1, and 5 μM concentrations, respectively. In HT144 cells, I3A caused aggregation of cells in G1 phase by 2.2%, 9.6%, and 16.2% at 0, 1, and 5 μM concentrations, respectively. In HT144 cells, I3A caused aggregation of cells in G1 phase by 4.2%, 16.5%, and 22.6% at 0, 1, and 5 μM concentrations, respectively. Remarkably, I3A also caused aggregation of cells in M phase by 8.5%, 15.1%, and 28.5% at 0, 1, and 5 μM concentrations, respectively. Cell cycle data suggest that I3A can cause G1 phase cell cycle arrest as well as G2/M phase arrest in both cell lines. These results collectively demonstrate that I3A caused induction of apoptosis in human melanoma cell lines and caused cell cycle arrest at G1 and G2/M phase.

I3A modulates apoptosis related proteins in melanoma cells

Because we found that I3A induced the mitochondrial intrinsic apoptosis pathway by activating caspase-9 and caspase-3, we further analyzed the expression of proteins in the apoptosis induction pathway. We examined the levels of pro- and
Figure 2. I3A induces apoptotic cells death and cell cycle arrest. (A) Flow cytometry analysis of A2058 and HT144 cells treated with or without I3A after annexin V/PI-FITC staining. (B) ELISA microplate measurement of mitochondrial membrane potential using JC-10 staining of A2058 and HT144 cells treated with or without I3A. Data represent percent of control from experimental triplicate. (C) Agarose gel electrophoresis of genomic DNA isolated from A2058 and HT144 cells treated with or without I3A. Percent colony formation is represented as compared to control. (D) Western blot analysis of apoptosis-related proteins from A2058 and HT144 cells treated with or without I3A. (E) Flow cytometry analysis of cell cycle from A2058 and HT144 cells treated with or without I3A after PI staining. Each quantitative experiment was performed in triplicate. I3A – ingenol-3-angelate; * P<0.05 vs. control.
anti-apoptosis Bcl-2 family proteins by Western blotting of proteins isolated from I3A-treated A2058 and HT144 cells (Figure 3A). BH3 interacting-domain death agonist (Bid) is a pro-apoptotic protein, which upon activation gets truncated (t-Bid) and translocates into mitochondria. I3A treatment of A2058 and HT144 cells caused a dramatic decrease in the levels of total Bid protein in a dose-dependent manner, suggesting that it might have truncated. Another pro-apoptotic protein, Bax, was found to be elevated by I3A treatment of A2058 and HT144 cells in a dose-dependent manner. t-Bid and Bax are known to initiate further apoptotic signaling inside mitochondria. We further observed that I3A treatment of A2058 and HT144 cells caused reduction in the levels of anti-apoptosis proteins Bcl-2 and Bcl-X, in a dose-dependent manner. Bcl-2 is a direct regulator of cytochrome c release from mitochondria, which was found to be elevated by I3A treatment of A2058 and HT144 cells in a dose-dependent manner. Cytochrome c released from mitochondria is recruited into apoptosome for caspase-9 activation, as shown in Figure 2D. Collectively, these results confirm that I3A induced mitochondrial intrinsic apoptotic pathway in human melanoma cells. Next, we examined the effect of I3A on apoptosis cascade in melanoma cell line in the presence of z-VAD-fmk (pan-caspase inhibitor). A2058 and HT144 cells were treated with z-VAD-fmk (5 μM) 1 h prior to 5-μM I3A treatment (Figure 3B). I3A treatment of cells showed activation of pro-caspase-3 and cleaved-caspase-3, as well as cleavage of PARP. Prior treatment of cells with z-VAD-fmk inhibited the activation of caspase-3 to a large extent. As expected, z-VAD-fmk-mediated inhibition of caspase-3 activation led to the inhibition of PARP cleavage to a greater extent. In addition, we also assessed the effect of I3A (5 μM) on viability of cells in the presence of z-VAD-fmk (5 μM). I3A (5 μM) treated A2058 and HT144 cells showed 48% and 46% viability, respectively (Figure 3C), while prior treatment of cells with z-VAD-fmk followed by I3A treatment showed increased viability of A2058 and HT144 cells by 86% and 78%, respective. Thus, treatment with z-VAD-fmk of A2058 and HT144 cells reverted the effects of I3A on both cell lines, but not fully. This observation also suggests that apoptosis induction is not the only phenomenon behind the effects of I3A on human melanoma cell lines, and other mechanistic events may intervene.

**I3A downregulates NF-κB signaling in human melanoma cells**

To investigate the mechanism behind the effects of I3A on human melanoma cells, we examined the effect on NF-κB signaling pathway and other associated signaling molecules. A2058 and HT144 cells were treated with I3A for 24 h and Western blotting was performed. Results show that I3A inhibited the levels of p65 subunit of NF-κB protein in a dose-dependent manner (Figure 4A). I3A also inhibited the phosphorylated form of p65 (p-p65) in a similar fashion in both cell lines. This indicated that I3A downregulates NF-κB activity in melanoma cells, which was further confirmed by analyzing the nuclear translocation of NF-κB proteins by Western blotting of nuclear and cytosolic fraction of A2058 and HT144 cells treated with I3A (Figure 4B). I3A (5 μM) effectively inhibited the nuclear translocation of p65 protein, as shown by dramatically reduced levels of p65 proteins in the nuclear fraction of both cell lines. We also examined the effect of I3A on gene levels of NF-κB and other signaling molecules by qPCR (Figure 4C). I3A suppressed the expression of NF-κB gene in a dose-dependent manner in both cell lines. This indicates that I3A downregulates the expression of NF-κB, which might cause the suppression of NF-κB protein in cytosolic fraction as well as its suppression of its nuclear translocation. In addition to NF-κB signaling, the effect of I3A was also examined on Cox-2 and iNOS proteins. Results interestingly demonstrate that I3A suppressed the levels of Cox-2 and iNOS of both proteins in A2058 and HT144 cell lines in a dose-dependent manner (Figure 4A). I3A suppressed the expression of iNOS and Cox-2 genes in both cell lines in a dose-dependent manner, with stronger suppression of iNOS (Figure 4C). We further assessed the dependence of I3A on NF-κB by using an NF-κB activator. Prostratin is a non-tumorigenic phorbol ester which activates NF-κB as well as PKC through activation of IIKs. Prostratin is a suitable NF-κB activator for this study, considering the NF-κB and PKC inhibitory properties of I3A. A2058 and HT144 cells were pretreated with a suboptimal concentration of prostratin (100 nM), which caused moderate activation of total-p65 as well as p-p65 proteins (Figure 4D). Prostratin-treated A2058 and HT144, cells when treated with I3A (5 μM), showed sustained levels of total-p65 and p-p65 proteins as compared to prostratin-negative cells. Cell viability was also assessed for A2058 and HT144 cells treated with prostratin and in combination with I3A (Figure 4E). Prostratin-treated A2058 and HT144 cells when treated with I3A (5 μM) showed sustained levels of total-p65 and p-p65 proteins as compared to prostratin-negative cells. A2058 and HT144 cells treated with I3A (5 μM) alone showed 42% and 48% cell survival as compared to control, and the difference was statistically significant. Pretreatment of A2058 and HT144 cells with prostratin (100 nM) alone showed 118% and 114% cell survival as compared to control, yet the difference was not statistically significant. Pretreatment of A2058 and HT144 cells with prostratin (100 nM) in combination with I3A (5 μM) showed 76% and 82% cell survival as compared to control, and the difference was statistically significant. It is noteworthy that prostratin reversed the effects I3A on cell survival; in contrast, I3A inhibited the cell survival even in the presence of NF-κB activator prostratin, possibly due to the interaction of I3A with NF-κB at the gene expression level. Results further indicate that I3A may act by downregulating NF-κB activity in human melanoma cells by inhibiting PKCs.
Figure 3. I3A induces intrinsic apoptosis pathway. (A, B) Western blot analysis of apoptosis related proteins from A2058 and HT144 cells treated with or without I3A. (C) MTT cell viability assay for A2058 and HT144 cells treated with or without I3A. Cell viability is represented as percent of control from experimental triplicates. I3A-1 – ingenol-3-angelate 1 μM; I3A-5 – ingenol-3-angelate 5 μM; z-VAD-fmk concentration 5 μM; * P<0.05 vs. control.
Figure 4. I3A downregulates NF-κB signaling. (A, B, D) Western blot analysis of proteins from A2058 and HT144 cells treated with or without I3A. (C) Quantitative real-time PCR analysis of NF-κB, iNOS, and Cox-2 genes from A2058 and HT144 cells treated with or without I3A. The data represented are fold changes (mean ±SD) of genes expression in I3A-treated samples vs. control (one-fold) from experimental triplicates. (E) MTT cell viability assay for A2058 and HT144 cells treated with or without I3A. Cell viability is represented as percent of control from experimental triplicates. I3A – ingenol-3-angelate; Cyt – cytosolic fraction; Nuc – nuclear fraction; prostratin concentration 100 nmol; * P<0.05 vs. control; ** P<0.05 vs. prostratin group.
I3A inhibits TPA-induced inflammation and epidermal hyperplasia

Skin hyperplasia is characterized by increased numbers of proliferating cells, leading to the gross enlargement of tissues. Microscopically, although they resemble normal tissue structure, the numbers of cells and their sizes increased. Thus, hyperplastic skin shows high epidermal thickness under induced conditions, as in TPA administration. The effect of I3A was studied in an animal model of skin carcinoma induced by topical application of TPA (10 nmol) in female ICR mice. Application of TPA (10 nmol) caused remarkable edema in skin epidermis and its invagination in toward the papillary and reticular layers of the dermis (Figure 5A). The epidermal thickness of skin was increased multifold due to TPA application (12.3±0.8 μm) as compared to control (5.6±0.4 μm) (Figure 5B). Furthermore, treatment of mice with I3A showed a dose-dependent improvement in skin structure and histology. TPA-induced increased epidermal thickness was suppressed to 9.8±0.7 and 7.1±0.6 μm by I3A treatment at 25 and 50 nmol concentrations, respectively (Figure 5B). The histological examination (Figure 5A, arrow) revealed more leukocytes infiltration in dermal layers due to the TPA application as compared control showing slight leukocyte localization toward epidermis. Furthermore, the leukocytes infiltration induced by TPA was dose-dependently inhibited by I3A treatment. These observations indicate the preventive role of I3A against TPA in mouse skin, which was further confirmed by IHC staining of molecular mediators of TPA-induced carcinoma Figure 5. PCNA is a marker of cell proliferation, an essential factor for DNA replication, DNA repair, chromatin remodeling, and epigenetics. The IHC analysis shows that TPA (10 nmol) application to mice caused a dramatic increase in the PCNA expression, by 182±12.6% as compared to control (100%). Further treatment of TPA-induced mice with I3A showed dose-dependent reduction in PCNA staining by 151±10.2 and 122±8.2% at 25 and 50 nmol of I3A, respectively. The IHC analysis shows that TPA (10 nmol) application caused apparent expression of Cox-2 in mice (314±12.8%) as compared to control, which was subsequently inhibited by I3A in a dose-dependent manner: 227±10.8 and 148±11.4% at 25 and 50 nmol of I3A, respectively. iNOS expression was similarly elevated by TPA application, which was subsequently suppressed by I3A in a dose-dependent manner: 227±10.8 and 148±11.4% at 25 and 50 nmol of I3A, respectively. In addition, we also performed qPCR from RNA isolated from skin tissues of mice (Figure 5C). Results show that TPA (10 nmol) application to mice caused dramatic increase in the expression levels of gene Cox-2, iNOS, and NF-kB genes. Further treatment of TPA-induced mice with I3A caused a dose-dependent reduction in the expression levels of all 3 genes. Inhibition of NF-kB by I3A in TPA-induced mice reveals the mechanistic approach behind effects of I3A. We also found that I3A suppressed the levels of AP-1, which were elevated by TPA application to mouse skin. These data further confirm that I3A downregulates NF-kB signaling, as observed from cell culture studies.

I3A inhibits DMBA-induced skin carcinoma in mice

To analyze the effect of I3A on DMBA-induced skin carcinogenesis, we first examined the external morphology of skin in mice of different groups. The skin of mice in the control group showed normal structural details. Mice treated with DMBA showed discrete skin ulcerations and papilloma growth, which was subsequently suppressed by treating mice with I3A. The tumor count analysis (Figure 6) showed no tumors in non-DMBA vehicle control. The DMBA treatment in mice caused a weekly increase in tumor growth per mouse, with an average count of 4.6±0.22 tumors per mouse at 16 weeks. Further treatment of DMBA-induced mice with I3A caused inhibition of tumor count in a dose-dependent manner. At 16 weeks, an average of 2.2±0.19 and 0.9±0.16 tumors were counted in I3A 25 and 50 nmol treatment groups, respectively. We observed that the incidence of papilloma growth started at week 4 and then aggravated after 6 weeks. In treatment groups, papilloma numbers started to gradually and then significantly reduce at 8 weeks onwards. We also observed that the sizes of papillomas in the DMBA-treated group were larger than in the DMBA-I3A-treated groups. More than 60% of papillomas in DMBA-treated mice were of ≥2.5 mm in diameter, but in the DMBA-I3A-treated groups less than 45% papillomas were of ≤2 mm in diameter. This observation indicates that I3A possibly inhibited the process of carcinogenesis.

I3A induces apoptosis in DMBA-induced mouse skin

We examined the effect of I3A on apoptosis in DMBA-induced mice by IHC for PCNA and activated caspase-3, TUNEL staining for apoptosis, and qPCR of apoptosis-related genes (Figure 7). The IHC analysis of proliferation marker PCNA shows that DMBA application caused a dramatic increase in the PCNA expression in mouse skin by 258±12.2% as compared to control (100%). Further treatment of DMBA-induced mice with I3A showed dose-dependent reduction in PCNA staining by 185±9.8 and 132±7.4% at 25 and 50 nmol of I3A, respectively (Figure 7A). Next, we analyzed the expression of activated caspase-3 (C-3A) in mouse skin. DMBA application reduced cellular apoptosis in skin sections as compared to the control group, which was subsequently activated by treatment with I3A in a dose-dependent manner (Figure 7B). The C-3A scoring for DMBA-induced mice was 236±11.3% as compared to control (100%), which was subsequently suppressed by I3A application to 168±7.4 and 128±6.8% at 25 and 50 nmol, respectively (Figure 7A). Cells stained for apoptotic bodies were drastically increased in DMBA-I3A-treated mice as compared to DMBA only. Figure 7C shows the quantitative scoring of TUNEL-positive cells, which
A

(i) VH

(ii) TPA (10 nmol)

(iii) TPA+I3A (25 nmol)

(iv) TPA+I3A (50 nmol)

B

PCNA

Cox-2

iNOS

C

Gene expression (fold change)

Cox-2

NF-κB

iNOS

AP-1

Figure 5. I3A suppresses TPA-induced inflammation in mouse skin. (A) H&E staining of skin sections of mice (n=3) induced with TPA (10 nmol) and treated with I3A at indicated concentrations. Quantitative epidermal thickness measurement (in μM) from mouse skin. a, vehicle control group; b, TPA (10 nmol); c, TPA+I3A (25 nmol); d, TPA+I3A (50 nmol). (B) IHC analysis of PCNA, Cox-2 and iNOS from skin sections of mice (n=3) induced with TPA (10 nmol) and treated with I3A at indicated concentrations. The graph represents the quantitative expression of staining of proteins vs. control (100%). (C) Quantitative real-time PCR analysis of Cox-2, iNOS, NF-κB, and AP-1 genes from skin of mice (n=3) induced with TPA (10 nmol) and treated with I3A at indicated concentrations. The data represented are fold changes (mean ±SD) of gene expression in I3A-treated samples vs. control (one-fold). I3A – ingenol-3-angelate; VH – vehicle control; * P<0.05 vs. control; ** P<0.05 vs. TPA group.
Figure 6. I3A suppresses skin tumor development in DMBA-induced mice. The tumor count from mouse skin was performed as described in the Methodology section. The data represented are mean ±SD of tumor counts in mouse groups at 2 weeks (n=5). I3A – ingenol-3-angelate; DMBA concentration 100 μg/100 μL of acetone. * P<0.05 vs. control.

Figure 7. I3A downregulates NF-κB signaling in DMBA-induced mice. IHC analysis of PCNA (A), activated caspase-3 (B), and TUNEL staining (C) from skin sections of mice (n=3) induced with DMBA (100 μg) and treated with I3A at indicated concentrations. The graph represents the quantitative expression of staining of proteins vs. control (100%). (D) Quantitative real-time PCR analysis of caspase-3, PARP, NF-κB, and TNF-α genes from skin of mice (n=3) induced with DMBA (100 μg) and treated with I3A at indicated concentrations. The data represented is fold change (mean ±SD) of genes expression in I3A-treated samples vs. control (one-fold). I3A – ingenol-3-angelate; VH – vehicle control; * P<0.05 vs. control; ** P<0.05 vs. DMBA group.
showed low levels of TUNEL-positive apoptotic cells in DMBA mice (42.1±5.6%) as compared to non-DMBA vehicle control (100%). Treatment of DMBA-induced mice with I3A at 25 and 50 nmol concentrations showed increased number of TUNEL positive apoptotic cells by 64.4±5.2% and 87.2±6.3%, respectively. These data show the pro-apoptotic properties of I3A in DMBA-induced mice. The effect of I3A on apoptosis in DMBA-induce mice was further confirmed by qPCR of 2 major apoptosis-related genes (caspase-3 and PARP). As observed from the results in human melanoma cells (Figures 2, 3), I3A induced the mitochondrial intrinsic apoptosis pathway; the same was observed from the gene expression analysis from DMBA-induced mouse skin (Figure 7D). I3A induced apoptosis cell death by activation of executioner caspase-3 followed by cleavage of nuclear substrate (PARP). The fold change in the expression of caspase-3 and PARP gene in DMBA-induced mice was 0.32- and 0.28-fold, respectively, as compared to control (Figure 7D). The expression levels of caspase-3 and PARP were dose-dependently elevated by I3A treatment. I3A (25 and 50 nmol) treatment increased the expression level of caspase-3 by 0.86- and 1.2-fold, respectively, as compared to control. Similarly, I3A (25 and 50 nmol) increased the expression level of PARP by 0.72- and 1.4-fold, respectively, as compared to control. The expression level of NF-κB and TNFα genes was also assessed from DMBA-induced mice. Results show that DMBA application caused the induction of NF-κB and TNFα genes in mice suppressed by I3A (25 and 50 nmol) treatment in a dose-dependent manner. Collectively, these data suggest that I3A suppressed DMBA-induced tumor growth in mice by activating apoptosis by downregulating NF-κB signaling.

Discussion

Many natural and synthetic agents have been used for treatment of various carcinomas in humans. Some natural metabolites and their analogues have gained clinical importance and are in clinical trials as well. In this study, we assessed the effect of ingenol-3-angelate as an anti-inflammatory and antitumor agent against human melanoma cells (A2058 and HT144) and TPA-induced inflammation in a mouse skin model and DMBA-induced skin carcinogenesis models. Results of the study demonstrate that I3A induced apoptosis in human melanoma cells by downregulating NF-κB signaling. I3A inhibited cellular inflammation by inhibiting Cox-2 and iNOS expression in melanoma cells. I3A suppressed the inflammation in mouse skin induced by TPA by downregulating NF-κB, Cox-2 and iNOS signaling. It also suppressed the cell proliferation events in TPA-induced mice. In DMBA-induced mice, I3A suppressed tumor growth by activating apoptosis by downregulating NF-κB signaling. Our results suggest that I3A has anti-inflammatory and antitumor properties in skin carcinoma.

Inflammation is a critical mediator of carcinogenesis by acting as a critical mediator of premalignant and malignant transformations [27]. Studies involving mouse skin models have elucidated the mechanism of inflammation in tumor promotion and have identified key signaling steps for targeting tumor progression [28]. Skin epidermis is mainly targeted by tumor promoters like TPA that cause acute inflammation and exaggerated expression of proinflammatory cytokines and chemokines. TPA acts as a potent tumor promoter by activating epidermal cell proliferation signaling, recruiting inflammatory cells, increasing production of reactive oxygen species (ROS), and inducing oxidative DNA damage. TPA elevates the expression of inflammatory enzymes like iNOS and COX-2, which mediate most known inflammatory processes leading to papilloma formation in skin [29]. COX-2 and iNOS upregulation has been associated with the pathophysiology of various cancer types as well as other inflammatory disorders [29]. Another major class of potent environmental carcinogens is DMBA, which is a prototype of polycyclic aromatic hydrocarbon used to promote tumors in experimental conditions. DMBA administration can induce mammary and skin tumors by upregulating the cellular cytotoxic receptor, the Aryl hydrocarbon receptor [14]. Activated Aryl hydrocarbon receptors can upregulate downstream signaling. DMBA further causes activation of NF-κB, which then positively controls transcriptional activity of cells proliferation [15]. Aryl hydrocarbon receptor and PCNA thus plays central role in xenobiotics-mediated carcinogenesis; thus, inhibiting the expression of Aryl hydrocarbon receptor may cause downregulation of NF-κB and inhibition of cell proliferation, which is presumably an important step in chemoprevention.

Modulation of novel signaling pathways like PKC mediates proximal regulation of keratinocyte viability and catalytic regulation of cutaneous squamous cell tumors [10,11]. I3A is an active natural molecule derived from Euphorbia peplus, which acts as a selective agonist of the PKC family, especially PKCβ and PKCε members. Studies report the preventive roles of I3A in various inflammatory and cancer conditions, including subcutaneous mouse and human tumor xenografts [20–24]. However, the effect of I3A on skin carcinoma remains unclear; so this study aimed to investigate the effect of I3A on growth of human melanoma cells and on mouse models of skin inflammation and carcinoma. Results of the study mainly demonstrate that I3A suppresses survival and proliferation of human melanoma cells and tumor growth in mice by activating apoptosis though downregulation of NF-κB signaling. The effect of I3A was analyzed on the growth and proliferation of human melanoma A2058 and HT144 cell lines (Figure 1). I3A suppressed the growth of both cells in a dose-dependent manner, with estimated IC50 values around 38 and 46 μM for A2058 and HT144 cell, respectively. Cells became apoptotic in morphology and showed reduced clonogenic property or suppressed cell proliferation. I3A activated the protein levels of...
PKCδ and PKCe in both A2058 and HT144 cell lines. These results confirmed that I3A suppresses survival and proliferation of melanoma cells by activating PKCs. Next, we observed that I3A induced apoptotic cell death and cell cycle arrest in human melanoma cells (Figure 2). I3A treatment of A2058 and HT144 cells showed early and late apoptosis responses, further confirmed by lowered ΔΨm and caused DNA fragmentation. The molecular mediator of I3A-induced apoptosis was via caspase-9-dependent activation of caspase-3 and cleavage of PARP. Activation of initiator caspase-9 and executioner caspase-3 suggests the activation of mitochondrial intrinsic apoptosis pathway in both cell lines treated with I3A. The cell cycle analysis indicated that I3A induced G1 phase cell cycle arrest, as well as G2/M phase arrest, in both cell lines. The mechanism behind these mixed observations needs elucidation. The apoptosis-inducing effects of I3A were further confirmed by using a pan-caspase inhibitor, z-VAD-fmk, which partially reversed the effects of I3A in A2058 and HT144 cells (Figure 3). The mechanism behind the effects of I3A was observed to be downregulation of NF-κB activity in human melanoma cells (Figure 4). I3A inhibited the levels of p65 subunit of NF-κB protein and it inhibited the phosphorylation of p65. I3A inhibited the nuclear translocation of p65 protein and it suppressed the expression of the NF-κB gene. I3A was found to suppress the protein levels of COX-2 and iNOS proteins. The effect of I3A on NF-κB downregulation was confirmed by using an NF-κB activator prostratin. Prostratin application partially limited the effects of I3A on A2058 and HT144 cells (Figure 4). NF-κB signaling governs multiple events in carcinogenic processes and tumor survival through suppression of apoptosis, inducing cell proliferation, and controlling the expression of genes involved in immune and inflammatory function [2–5]. NF-κB acts as a transcriptional upregulator of COX-2; thus, downregulation of the NF-κB signaling pathway limits COX-2 activity in crosstalk with iNOS. I3A-mediated inhibition of NF-κB also correlates with the inhibition of anti-apoptotic proteins Bcl-xL and Bcl-2 (Figure 3A), as they are transcriptionally regulated by NF-κB. NF-κB downregulation in turn correlates with the suppression of cell proliferation and activation of apoptosis by I3A. Sensitization of colon cancer cells with TNF-α showed induction of COX-2 through NF-κB-mediated transcriptional upregulation [4]. The NF-κB/Rel family contains 5 members: RelA (p65), c-Rel, RelB, NF-κB1 (p105/p50), and NF-κB2 (p100/ p52). Among these subunits of NF-κB, phosphorylation of p65 subunit is known to directly stimulate COX-2 expression [30].

In mouse models of skin inflammation and cancer, I3A acted as a potent inhibitor of inflammation and tumor growth. I3A inhibits TPA-induced inflammation and epidermal hyperplasia in female ICR mice (Figure 5). TPA application to ICR mice caused remarkable edema and leukocyte infiltration and increased epidermal thickness, which were effectively suppressed by I3A administration. The IHC analysis showed that TPA-induced PCNA was effectively suppressed by I3A. PCNA is a marker of cell proliferation, an essential factor for DNA replication, DNA repair, chromatin remodeling, and epigenetics. The IHC analysis shows that TPA (10 nmol) application to mice caused a dramatic increase in PCNA expression, which was subsequently suppressed by I3A treatment. IHC analysis also showed that TPA-induced COX-2 and iNOS expressions were suppressed by I3A. Also I3A suppressed the gene expression of COX-2, iNOS, NF-κB, and AP-1 genes as analyzed by qPCR (Figure 5). AP-1 is a transcription factor that regulates expression of various genes functioning in response to a variety of stimuli, including inflammation. In conjunction with NF-κB, AP-1 transcriptionally controls various cellular events like differentiation, proliferation, and apoptosis. Next, we analyzed the effect of I3A on DMBA-induced skin carcinoma in mice. I3A was found to improve the morphological changes induced by DMBA in mouse skin. I3A suppressed the growth of skin tumor in DMBA-induced mice (Figure 6). At 16 weeks, I3A application suppressed tumor growth by approximately 52% and 80% at 25 and 50 nmol concentrations, respectively. I3A was found to induce apoptosis in DMBA-induced mice (Figure 7). I3A suppressed the DMBA-induced high levels of PCNA in mouse skin. I3A further enhanced the expression of activated caspase-3 and TUNEL-positive cells in mouse skin. The qPCR of caspase-3 and PARP confirmed that I3A inhibits the expression of cell proliferation marker and activates apoptosis. I3A was found to suppress the expression of the NF-κB gene, which was elevated by DMBA application.

**Conclusions**

Results of the study demonstrate that I3A induced apoptosis in human melanoma cells lines by downregulating NF-κB signaling. NF-κB downregulation also resulted in suppression of inflammatory signaling in cells. I3A was highly effective in suppressing inflammation in ICR mouse skin induced by TPA through downregulation of NF-κB and COX-2 signaling together with iNOS. Likewise, I3A was found to be a potent tumor-suppressor molecule against DMBA-induced skin carcinoma in mice. The growing interest in natural prevention of cancer has explored various safe and efficacious therapeutic agents with potentials to inhibit cancer growth in cell cultures and in animal models. I3A is advocated to be used as a potent anti-tumor agent with anti-inflammatory properties.

**Conflict of interest**

None.
References:

1. Lu H, Ouyang W, Huang C: Inflammation, a key event in cancer development. Mol Cancer Res, 2006; 4: 221–33
2. Coussens LM, Werb Z: Inflammation and cancer. Nature, 2002; 420: 860–67
3. Yamamoto Y, Gaynor RB: Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest, 2001; 107: 135–42
4. Wang S, Liu Z, Wang L, Zhang X: NF-kappaB signaling pathway, inflammation and colorectal cancer. Cell Mol Immunol, 2009; 6: 327–34
5. Pikarsky E, Porat RM, Stein I et al: NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature, 2004; 431: 461–66
6. Wang MT, Hopp KV, Nie D: Cyclooxygenases, prostanooids, and tumor progression. Cancer Metastasis Rev, 2007; 26: 525–34
7. Takahashi T, Baba M, Nishino H, Okuyama T: Cyclooxygenase-2 plays a suppressive role for induction of apoptosis in isoliquiritigenin-treated mouse colon cancer cells. Cancer Lett, 2006; 231: 319–25
8. Lau GT, Ye L, Leung LK: The licorice flavonoid isoliquiritigenin suppresses phorbol ester-induced cyclooxygenase-2 expression in the non-tumorigenic MCF-10A breast cell line. Planta Med, 2009; 76: 780–85
9. Boolbol SK, Dannenberg AJ, Chadburn A et al: Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res, 1996; 56: 2556–60
10. D’Costa AM, Robinson JK, Maududi T et al: The proapoptotic tumor suppressor protein kinase C-delta is lost in human squamous cell carcinomas. Oncogene, 2006; 25: 378–86
11. Denning MF, Wang Y, Nickoloff BJ, Wrone-Smith A et al: Protein kinase C-delta is activated by caspase-dependent proteolysis during ultraviolet radiation-induced apoptosis of human keratinocytes. J Biol Chem, 1998; 273: 29995–30002
12. Chun KS, Keum YS, Han SS et al: Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis, 2003; 24: 1515–24
13. Chun KS, Kim SH, Song YS, Suh YJ: Celecoxib inhibits phorbol ester-induced expression of COX-2 and activation of AP-1 and p38 MAP kinase in mouse skin. Carcinogenesis, 2004; 25: 713–22
14. Abel EL, Angel JM, Kiguchi K, DiGiovanni J: Multi-stage chemical carcinogenesis in mouse skin: Fundamentals and applications. Nat Protoc, 2009; 4: 1350–62
15. Brantley DM, Chen CL, Muraoka RS et al: Nuclear factor-kappaB (NF-kappaB) regulates proliferation and branching in mouse mammary epithelium. Mol Biol Cell, 2001; 12: 1445–55
16. Kundu IK, Shin YK, Kim SH, Suh YJ: Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis, 2006; 27: 1465–74
17. Kang HJ, Jang JE, Mishra SK et al: Ergosterol peroxide from Chaga mushroom (Inonotus obliquus) exhibits anti-cancer activity by down-regulation of the beta-catenin pathway in colorectal cancer. J Ethnopharmacol, 2015; 173: 303–12
18. Mishra SK, Kang J-H, Song K-H et al: Inonotus obliquus suppresses proliferation of colorectal cancer cells and tumor growth in mice models by downregulation of beta-catenin/NF-kB-signaling pathways. European Journal of Inflammation, 2013; 11: 615–29
19. Mishra SK, Kang JH, Kim DK et al: Orally administered aqueous extract of Inonotus obliquus ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice. J Ethnopharmacol, 2012; 143: 524–12
20. Ogbourne SM, Subhrier A, Jones B et al: Antitumor activity of 3-ingenylangelate: plasma membrane and mitochondrial disruption and necrotic cell death. Cancer Res, 2004; 64: 2833–39
21. Lehwohl M, Swanson N, Anderson LL et al: Ingenol mebutate gel for actinic keratosis. N Engl J Med, 2012; 366: 1010–19
22. Hampson P, Chahal H, Khanim F et al: PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood, 2005; 106: 1362–68
23. Mason SA, Cozzi SL, Pierce CJ et al: The induction of senescence-like growth arrest by protein kinase C-activating diterpene esters in solid tumor cells. Invest New Drugs, 2010; 28: 575–86
24. Gillespie SK, Zhang XD, Hersey P: Ingenol 3-angelate induces dual modes of cell death and differentially regulates tumor necrosis factor-related apoptosissuppressing ligand-induced apoptosis in melanoma cells. Mol Cancer Ther, 2004; 3: 1651–58
25. Li L, Shukla S, Lee A et al: The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature. Cancer Res, 2010; 70: 4509–19
26. Challacombe JM, Subhrier A, Parsons PG et al: Neutrophils are a key component of the antitumor efficacy of topical chemotherapy with ingenol-3-angelate. J Immunol, 2006; 177: 8123–32
27. Balkwill F, Coussens LM: Cancer: An inflammatory link. Nature, 2004; 431: 461–66
28. Wu X, Pandolfi PP: Mouse models for multistep tumorigenesis. Trends Cell Biol, 2001; 11: 52–9
29. Ohshima H, Tazawa H, Sylla BS, Sawa T: Prevention of human cancer by modulation of Inflammation, a key event in cancer development. Mol Cancer, 2004; 3: 1651–58
30. Poligone B, Baldwin AS: Positive and negative regulation of NF-kappaB by I kappaB-signaling pathways. European Journal of Immunology, 2013; 11: 615–29
31. Wang D. et al.: Ingenol-3-angelate suppresses skin inflammation and carcinoma progression. J Med Sci Monit, 2018; 24: 486-502

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)